Wire flash
FDA advisory panel votes to recommend six unproven peptides, sparking safety concerns
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
An FDA advisory panel voted to recommend adding six unproven peptides to the list of drugs compounding pharmacies can sell, despite safety and efficacy concerns. The vote was influenced by Health Secretary Robert F. Kennedy Jr., who added eight new members to the panel, six of whom run clinics offering these chemicals. Proponents argue that thousands already use potentially dangerous black market peptides and that regulated access would be safer. Critics, including FDA scientists, cite the absence of clinical trial data and risk of harmful immune reactions. The decision is seen as part of a broader push to bypass strict FDA evidence standards in the wellness-focused telehealth era, with experts warning of a 'Wild West market' for untested drugs.
Source report
An FDA advisory panel has voted to recommend adding six unproven peptides to the list of custom drugs that compounding pharmacies can sell, sparking debate over safety, regulation, and the growing wellness market.
The Vote and Its Controversy
According to Tom Bartlett in The Atlantic, an FDA advisory panel voted last month to recommend that six unproven peptides be added to the list of custom drugs available through so-called compounding pharmacies. Peptides are chains of amino acids that instruct cells to regulate biological processes; some, such as insulin and GLP-1s, are FDA-approved medicines.
However, pharmacies were banned in 2023 from dispensing these six peptides—which proponents claim offer benefits ranging from improved endurance to reduced inflammation—due to efficacy and safety concerns.
Health Secretary Robert F. Kennedy Jr., a peptides enthusiast, added eight new members to the panel ahead of the vote. Six of those appointees run clinics that offer the chemicals. While the vote is only a recommendation, "ultimate approval seems likely"—to the delight of sellers anticipating a "peptide gold rush" and the dismay of experts who fear opening a "Pandora's box."
Surging Demand and the Gray Market
Demand for injectable peptides is surging, "thanks to the endorsement of podcasters, wellness influencers," and celebrities, reports Emily Mullin in Wired. Among the chemicals approved by the panel are two that combine to form the Joe Rogan–backed "Wolverine stack," which is said to aid injury recovery.
Undeterred by the lack of evidence, users currently buy peptides on the "unregulated gray market." The chemicals are sourced from labs in China and India and sold as "for research use only."
Deep Divide Between Kennedy Appointees and FDA Scientists
The vote "exposed a deep divide" between Kennedy's appointees and FDA scientists, according to Yonathan Daniel in ABCNews.com. Scientists cited the absence of clinical trial data and the risk of harmful immune reactions. Proponents, however, argued that thousands of people already take potentially dangerous black market peptides, and that the agency should protect them by granting access to safer products.
Broader Implications for FDA Standards
This isn't "just about peptides," writes Julia Belluz in The New York Times. It's "part of a broader push" to increase access to drugs that haven't met "the strict evidence standards the FDA usually requires." The agency "wasn't designed for this wellness-crazed" telehealth era, in which Americans are "going outside the bounds of traditional health care in growing numbers."
But the FDA is "the only thing standing between consumers and a Wild West market" for untested and potentially harmful drugs. "There has to be a better way forward" than dropping standards and allowing consumer demand to override "scientific evidence."
The Week
Source
TheWeek feedWestern
Part of this Story
FDA Panel Votes to Ease Restrictions on Unproven Wellness Peptides